The United States is witnessing strong adoption of intravenous immunoglobulin (IVIG) therapy due to the rising prevalence of autoimmune diseases, primary immunodeficiency disorders, and neurological conditions. Advanced healthcare infrastructure, widespread availability of plasma-derived therapies, and favorable reimbursement policies continue to support treatment accessibility across...

The United States represents a significant market for human rabies immunoglobulin due to its well-established healthcare infrastructure, widespread availability of post-exposure prophylaxis treatments, and strong public health surveillance systems. Although human rabies cases remain relatively rare in the country, healthcare providers maintain strict protocols for managing potential rabies...